New birth control pill aims to cut estrogen while boosting effectiveness

NCT ID NCT07714616

Not yet recruiting Disease control Sponsor: Eurofarma Laboratorios S.A. Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests a new birth control pill that combines a lower dose of estrogen with a progestogen that also blocks male hormones. About 1,600 women aged 14 to 45 will take the pill daily for 13 cycles (about a year) to see how well it prevents pregnancy and to check for side effects. The goal is to offer an effective contraceptive with potentially fewer hormone-related issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a new birth control pill containing cyproterone acetate 2 mg and ethinyl estradiol 0.02 mg
What this could lead to: If successful, this could provide a new, effective birth control option with a lower estrogen dose and antiandrogenic benefits for women.
What could go wrong: This is a single-arm trial without a comparison group, so results may be less definitive. Side effects typical of hormonal contraceptives, such as blood clots, mood changes, and breakthrough bleeding, remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRACEPTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTRACEPTION

More trials for these conditions

Other studies related to the condition(s) this trial covers.